Adaptive Biotechnologies (ADPT) Other Operating Expenses (2018 - 2026)

Adaptive Biotechnologies has reported Other Operating Expenses for 9 years, with the latest figure at $42.1 million in Q1 2026.

• Quarterly Other Operating Expenses rose 4.11% year-over-year to $42.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.5 million (down 9.69% YoY) and the FY2025 annual result came in at $167.6 million, down 7.86% from the prior year.
• Other Operating Expenses slipped to $42.1 million in Q1 2026 per ADPT's latest filing, from $43.1 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $58.2 million in Q4 2024 and troughed at $36.8 million in Q3 2022.
• A 5-year average of $43.3 million and a median of $42.0 million in 2025 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses soared 42.95% in 2024, then fell 25.83% in 2025.
• Over 5 years, Other Operating Expenses stood at $40.7 million in 2022, then slipped by 0.13% to $40.7 million in 2023, then jumped by 42.95% to $58.2 million in 2024, then dropped by 25.83% to $43.1 million in 2025, then declined by 2.38% to $42.1 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $42.1 million, $43.1 million, and $42.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.